Ovarian Cancer Hemoscope Trial

NCT02811224Active, Not RecruitingOBSERVATIONAL

Summary

Key Facts

Lead Sponsor

Scripps Translational Science Institute

Enrollment

50

Start Date

2016-05-01

Completion Date

2025-06-01

Study Type

OBSERVATIONAL

Conditions

Ovarian Neoplasms

Eligibility

Age Range

18 Years+

Sex

FEMALE

Inclusion Criteria:

Case Group

* Patients with ovarian cancer undergoing surgery (all stages)
* Over 18 years old

Control Group

* Patients with a benign gynecological condition undergoing surgery
* Over 18 years old

Exclusion Criteria:

* Previous cancer diagnosis (all)
* Radiation therapy before surgical treatment
* Bone marrow transplant
* Chemotherapy before surgical treatment
* Invasive procedure resulting in damage to tissue (e.g., surgery, biopsy, thermal ablation) in the 7 days prior to baseline (pre-surgical) blood collection

Outcome Measures

Primary Outcomes

Sensitivity of an assay that detects circulating tumor DNA

Time frame: 3 years

Ovarian Cancer Hemoscope Trial